Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984977265> ?p ?o ?g. }
- W2984977265 endingPage "e1002960" @default.
- W2984977265 startingPage "e1002960" @default.
- W2984977265 abstract "Background Young male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy or effects of chemotherapy and radiotherapy. We have undertaken a double-blind, placebo-controlled, 6-month trial of testosterone replacement in young male cancer survivors with borderline low testosterone (7–12 nmol/l). Methods and findings This was a multicentre United Kingdom study conducted in secondary care hospital outpatients. Male survivors of testicular cancer, lymphoma, and leukaemia aged 25–50 years with morning total serum testosterone 7–12 nmol/l were recruited. A total of 136 men were randomised between July 2012 and February 2015 (42.6% aged 25–37 years, 57.4% 38–50 years, 88% testicular cancer, 10% lymphoma, matched for body mass index [BMI]). Participants were randomised 1:1 to receive testosterone (Tostran 2% gel) or placebo for 26 weeks. A dose titration was performed after 2 weeks. The coprimary end points were trunk fat mass and SF36 Physical Functioning score (SF36-PF) at 26 weeks by intention to treat. At 26 weeks, testosterone treatment compared with placebo was associated with decreased trunk fat mass (−0.9 kg, 95% CI −1.6 to −0.3, p = 0.0073), decreased whole-body fat mass (−1.8 kg, 95% CI −2.9 to −0.7, p = 0.0016), and increased lean body mass (1.5 kg, 95% CI 0.9–2.1, p < 0.001). Decrease in fat mass was greatest in those with a high truncal fat mass at baseline. There was no treatment effect on SF36-PF or any other QoL scores. Testosterone treatment was well tolerated. The limitations of our study were as follows: a relatively short duration of treatment, only three cancer groups included, and no hard end point data such as cardiovascular events. Conclusions In young male cancer survivors with low-normal morning total serum testosterone, replacement with testosterone is associated with an improvement in body composition. Trial registration ISRCTN: 70274195, EudraCT: 2011-000677-31." @default.
- W2984977265 created "2019-11-22" @default.
- W2984977265 creator A5003887123 @default.
- W2984977265 creator A5004159963 @default.
- W2984977265 creator A5013663330 @default.
- W2984977265 creator A5018216064 @default.
- W2984977265 creator A5022792601 @default.
- W2984977265 creator A5025494836 @default.
- W2984977265 creator A5030816592 @default.
- W2984977265 creator A5044930092 @default.
- W2984977265 creator A5047234703 @default.
- W2984977265 creator A5051980635 @default.
- W2984977265 creator A5070460232 @default.
- W2984977265 creator A5087965953 @default.
- W2984977265 date "2019-11-12" @default.
- W2984977265 modified "2023-10-05" @default.
- W2984977265 title "Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial" @default.
- W2984977265 cites W1935834387 @default.
- W2984977265 cites W1971278207 @default.
- W2984977265 cites W1989998099 @default.
- W2984977265 cites W1995567287 @default.
- W2984977265 cites W1998884854 @default.
- W2984977265 cites W2001118572 @default.
- W2984977265 cites W2015758016 @default.
- W2984977265 cites W2064710061 @default.
- W2984977265 cites W2076643649 @default.
- W2984977265 cites W2082845839 @default.
- W2984977265 cites W2091830006 @default.
- W2984977265 cites W2108362230 @default.
- W2984977265 cites W2109494488 @default.
- W2984977265 cites W2109964083 @default.
- W2984977265 cites W2123994640 @default.
- W2984977265 cites W2136361773 @default.
- W2984977265 cites W2140409181 @default.
- W2984977265 cites W2145908651 @default.
- W2984977265 cites W2149564130 @default.
- W2984977265 cites W2307314017 @default.
- W2984977265 cites W2324158400 @default.
- W2984977265 cites W2409486903 @default.
- W2984977265 cites W2746751342 @default.
- W2984977265 cites W2791298691 @default.
- W2984977265 cites W2810587994 @default.
- W2984977265 cites W2900948201 @default.
- W2984977265 cites W2917244549 @default.
- W2984977265 doi "https://doi.org/10.1371/journal.pmed.1002960" @default.
- W2984977265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6850530" @default.
- W2984977265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31714912" @default.
- W2984977265 hasPublicationYear "2019" @default.
- W2984977265 type Work @default.
- W2984977265 sameAs 2984977265 @default.
- W2984977265 citedByCount "16" @default.
- W2984977265 countsByYear W29849772652020 @default.
- W2984977265 countsByYear W29849772652021 @default.
- W2984977265 countsByYear W29849772652022 @default.
- W2984977265 countsByYear W29849772652023 @default.
- W2984977265 crossrefType "journal-article" @default.
- W2984977265 hasAuthorship W2984977265A5003887123 @default.
- W2984977265 hasAuthorship W2984977265A5004159963 @default.
- W2984977265 hasAuthorship W2984977265A5013663330 @default.
- W2984977265 hasAuthorship W2984977265A5018216064 @default.
- W2984977265 hasAuthorship W2984977265A5022792601 @default.
- W2984977265 hasAuthorship W2984977265A5025494836 @default.
- W2984977265 hasAuthorship W2984977265A5030816592 @default.
- W2984977265 hasAuthorship W2984977265A5044930092 @default.
- W2984977265 hasAuthorship W2984977265A5047234703 @default.
- W2984977265 hasAuthorship W2984977265A5051980635 @default.
- W2984977265 hasAuthorship W2984977265A5070460232 @default.
- W2984977265 hasAuthorship W2984977265A5087965953 @default.
- W2984977265 hasBestOaLocation W29849772651 @default.
- W2984977265 hasConcept C120863210 @default.
- W2984977265 hasConcept C121608353 @default.
- W2984977265 hasConcept C126322002 @default.
- W2984977265 hasConcept C142724271 @default.
- W2984977265 hasConcept C147583825 @default.
- W2984977265 hasConcept C204787440 @default.
- W2984977265 hasConcept C27081682 @default.
- W2984977265 hasConcept C2779279991 @default.
- W2984977265 hasConcept C2780221984 @default.
- W2984977265 hasConcept C71924100 @default.
- W2984977265 hasConceptScore W2984977265C120863210 @default.
- W2984977265 hasConceptScore W2984977265C121608353 @default.
- W2984977265 hasConceptScore W2984977265C126322002 @default.
- W2984977265 hasConceptScore W2984977265C142724271 @default.
- W2984977265 hasConceptScore W2984977265C147583825 @default.
- W2984977265 hasConceptScore W2984977265C204787440 @default.
- W2984977265 hasConceptScore W2984977265C27081682 @default.
- W2984977265 hasConceptScore W2984977265C2779279991 @default.
- W2984977265 hasConceptScore W2984977265C2780221984 @default.
- W2984977265 hasConceptScore W2984977265C71924100 @default.
- W2984977265 hasFunder F4320319985 @default.
- W2984977265 hasIssue "11" @default.
- W2984977265 hasLocation W29849772651 @default.
- W2984977265 hasLocation W29849772652 @default.
- W2984977265 hasLocation W29849772653 @default.
- W2984977265 hasLocation W29849772654 @default.
- W2984977265 hasLocation W29849772655 @default.
- W2984977265 hasOpenAccess W2984977265 @default.
- W2984977265 hasPrimaryLocation W29849772651 @default.